How Emergent BioSolutions profited from Narcan’s over-the-counter delay - The Washington Post
washingtonpost.comSubmitted by thewashingtonpost7104 in health
Access to Narcan, a lifesaving drug that reverses overdoses, has been limited by Emergent BioSolutions’ hunt for profits, including a five-year delay in bringing it over the counter.